8-K: EyePoint Pharmaceuticals Accelerates Wet AMD Trial Enrollment, Anticipates Mid-2026 Data for DURAVYU

EyePoint Pharmaceuticals, Inc. announced the completion of enrollment for its pivotal Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration (wet AMD), significantly ahead of schedule, with topline data expected in mid-2026.

Summary

• EyePoint Pharmaceuticals has completed enrollment for its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for wet age-related macular degeneration (wet AMD), enrolling over 400 patients in seven months.
• The rapid enrollment of the LUGANO trial is noted as one of the fastest for a Phase 3 pivotal trial in wet AMD to date.
• Topline 56-week data for the LUGANO trial is now anticipated in mid-2026.
• The second pivotal Phase 3 trial, LUCIA, continues rapid enrollment with 60% of patients randomized, and full enrollment is expected in Q3 2025, with topline data to follow in the second half of 2026.
• DURAVYU (formerly EYP-1901) is an investigational sustained delivery therapy delivering vorolanib, a patent-protected tyrosine kinase inhibitor (TKI), using EyePoint's bioerodible Durasert E technology.
• The Phase 3 program for DURAVYU was developed in alignment with the U.S. Food and Drug Administration (FDA) and is designed as non-inferiority trials against an aflibercept control.
• Positive data from previous Phase 1 and Phase 2 (DAVIO 2) trials in wet AMD demonstrated clinically meaningful efficacy, stable visual acuity, and a favorable safety profile, with an approximately 88% reduction in treatment burden six months post-treatment in DAVIO 2.
• DURAVYU is also being evaluated for diabetic macular edema (DME), with Phase 2 VERONA trial results showing immediate and sustained improvement in vision and anatomy, and a favorable safety profile.
• An End-of-Phase 2 (EOP2) meeting with the FDA for the DME program is scheduled for July 2025.
• The company reported $318 million in cash and cash equivalents as of March 31, 2025, providing a cash runway into 2027, beyond the anticipated LUGANO and LUCIA data readouts.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significantly accelerated enrollment of a pivotal Phase 3 trial, which de-risks the clinical development timeline and indicates strong market interest. Positive Phase 2 data and a solid cash runway further bolster confidence, despite inherent risks in biopharmaceutical development and existing regulatory/legal uncertainties.

Positives

• Completion of enrollment for the pivotal Phase 3 LUGANO trial for DURAVYU in wet AMD was achieved in a record seven months, exceeding enrollment targets and demonstrating strong physician and patient interest.
• The LUGANO trial's rapid enrollment pace is one of the fastest for a wet AMD Phase 3 pivotal trial to date, indicating high enthusiasm for DURAVYU's potential.
• The LUCIA pivotal Phase 3 trial is also progressing rapidly, with 60% of patients randomized and full enrollment expected ahead of schedule in Q3 2025.
• Topline data for LUGANO is now expected in mid-2026, and for LUCIA in 2H 2026, providing clear timelines for key clinical milestones.
• DURAVYU has demonstrated a robust safety and efficacy profile in over 190 patients across multiple indications, including positive Phase 2 DAVIO 2 data in wet AMD and VERONA data in DME.
• The VERONA Phase 2 trial in DME met its primary and secondary endpoints, showing immediate and sustained improvement in vision and anatomy, supporting advancement to a Phase 3 program.
• The company has a strong cash position of $318 million as of March 31, 2025, providing a cash runway into 2027, which extends beyond the anticipated Phase 3 data readouts for both LUGANO and LUCIA.
• DURAVYU's mechanism of action (TKI) and sustained-delivery technology (Durasert E) offer a potential new treatment paradigm for chronic retinal diseases, addressing the significant unmet need for more durable therapies.
• The company operates a state-of-the-art cGMP manufacturing facility in Northbridge, MA, built to US FDA and EU EMA standards, supporting future commercial production.

Risks

• Uncertainties and delays related to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU.
• Unanticipated costs and expenses that could impact the company's financial runway.
• The risk that results of clinical trials may not be predictive of future results, and interim/preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data observed during ongoing or future clinical trials.
• Uncertainties related to the regulatory authorization or approval process and available development pathways for product candidates.
• Changes in the regulatory environment or disruptions at the FDA, including due to workforce reductions or inadequate funding.
• Changes in U.S. and international trade policies.
• Changes in expected or existing competition for retinal disease treatments.
• Dependence on contract research organizations (CROs) and other outside vendors/service providers.
• Potential product liability claims.
• Impact of general business and economic conditions.
• Challenges in protecting intellectual property and avoiding infringement.
• Difficulty in retaining key personnel.
• Delays, interruptions, or failures in the manufacture and supply of product candidates.
• The availability of and the need for additional financing to support clinical development programs.
• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the company's Watertown, MA manufacturing facility.

Future Outlook

EyePoint Pharmaceuticals anticipates topline data for the LUGANO trial in mid-2026, followed by LUCIA data in the second half of 2026. The company expects to complete enrollment for the LUCIA trial in Q3 2025 and plans an End-of-Phase 2 meeting with the FDA in July 2025 to solidify plans for a pivotal DME program. Management expresses optimism that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME and improve patient outcomes, aiming to be the first sustained-release TKI to market.

Management Comments

• "The rapid enrollment of the Phase 3 LUGANO trial is a testament to the significant patient and physician enthusiasm for our Phase 3 program and underscores the tremendous commercial market potential for DURAVYU." Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint.
• "We are committed to bringing the first sustained-release TKI to market for patients and physicians in need of a new treatment option for wet AMD." Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint.
• "With both pivotal trials continuing to exceed our timelines, we now expect topline data for the LUGANO trial in mid-2026 with LUCIA to follow in the second half of 2026." Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint.
• "The excitement for DURAVYU within the retinal community highlights its potential to transform the treatment paradigm for wet AMD patients. It also reflects the strong appeal of our trial design, which is supported by a well-established safety profile in over 190 patients." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint.
• "With enrollment in the LUGANO trial completed, our focus is on completing enrollment for the LUCIA trial in the third quarter of 2025. We expect continued strong momentum, with sites outside the US now actively enrolling along with select LUGANO sites preparing to cross over to LUCIA." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint.
• "The pace of enrollment in the LUGANO trial highlights EyePoint's engagement with the retinal community and underscores the enthusiasm for DURAVYU and the patient-centric pivotal program." Brittney Statler, M.D., Principal Investigator in the LUGANO clinical trial and Medical Retina Specialist at Panorama Eyecare.
• "One of the many compelling elements of this program is the fact that all patients receive active treatment with either aflibercept or DURAVYU enabling us to effectively evaluate the potential next generation of treatment for wet AMD in clinical practice." Brittney Statler, M.D., Principal Investigator in the LUGANO clinical trial and Medical Retina Specialist at Panorama Eyecare.

Industry Context

The announcement highlights EyePoint's strong position in developing sustained-release therapies for chronic retinal diseases like wet AMD and DME, which currently require frequent intravitreal injections (e.g., every two months for standard-of-care anti-VEGFs). The company addresses a significant unmet need for more durable treatments, as frequent dosing leads to patient noncompliance, treatment burden, and potential vision loss. DURAVYU, as a sustained-delivery TKI, aims to offer a less frequent dosing regimen (potentially every six months), which could revolutionize the treatment paradigm and improve patient adherence and outcomes, positioning EyePoint as a leader in ocular sustained drug delivery.

Comparison to Industry Standards

• DURAVYU is being evaluated in non-inferiority Phase 3 trials (LUGANO and LUCIA) against aflibercept (Eylea), a current standard-of-care anti-VEGF treatment, with patients randomized to either DURAVYU 2.7mg or on-label aflibercept 2mg.
• The LUGANO and LUCIA trials are unique as the only sustained-release wet AMD pivotal Phase 3 trials evaluating 6-month redosing over two years, a significant improvement over the average two-month dosing of current anti-VEGFs in the U.S. under a treat-and-extend protocol.
• Phase 2 DAVIO 2 data for DURAVYU in wet AMD demonstrated statistical non-inferiority in best corrected visual acuity (BCVA) compared to aflibercept, along with an impressive treatment burden reduction of approximately 88% six months after treatment.
• In DME, the Phase 2 VERONA trial showed DURAVYU's potential for superior dosing intervals compared to standard of care, with a single DURAVYU 2.7mg treatment demonstrating clinically meaningful improvement in BCVA (+7.1 letters) and central subfield thickness (CST) reduction (-76 microns) at 24 weeks, comparable to or better than aflibercept's single injection results.
• DURAVYU's mechanism (pan-VEGF receptor inhibitor) is differentiated from current large molecule anti-VEGF treatments that only target one pathology, potentially offering broader benefits like neuroprotection and anti-fibrotic effects.

Management Changes

Legal Proceedings

• Uncertainties regarding the timing and results of an August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding an FDA warning letter pertaining to the company's Watertown, MA manufacturing facility.

Stakeholder Impact

• **Shareholders:** Positive clinical trial progress and accelerated timelines could lead to increased investor confidence and potential share price appreciation, while inherent biopharma risks and regulatory/legal uncertainties remain.
• **Patients:** The potential for a sustained-delivery treatment like DURAVYU could significantly reduce treatment burden (fewer injections) and improve adherence, leading to better visual outcomes for patients with wet AMD and DME.
• **Physicians:** DURAVYU offers a new, more durable treatment option that could simplify patient management and reduce the frequency of in-office injections, addressing a key need expressed by retina specialists.
• **Employees:** Continued positive clinical development and potential commercialization could lead to job stability and growth opportunities within the company.
• **Regulatory Authorities:** The company's direct alignment with the FDA on trial design and ongoing communication (e.g., EOP2 meeting) indicates a structured approach to regulatory approval.

Next Steps

• Complete full enrollment of the LUCIA Phase 3 trial in wet AMD in Q3 2025.
• Hold an End-of-Phase 2 (EOP2) meeting with the FDA in July 2025 to solidify plans for the DME pivotal program.
• Release topline data for the LUGANO Phase 3 trial in mid-2026.
• Release topline data for the LUCIA Phase 3 trial in the second half of 2026.
• Continue clinical development of other product candidates, including EYP-2301.

Key Dates

Recommendation

Keywords

EyePoint Pharmaceuticals, DURAVYU, wet AMD, age-related macular degeneration, DME, diabetic macular edema, LUGANO trial, LUCIA trial, Phase 3 clinical trial, vorolanib, tyrosine kinase inhibitor, TKI, Durasert E, sustained delivery, retinal diseases, ophthalmology, biopharmaceutical, clinical-stage, FDA approval, clinical trial enrollment, DAVIO 2, VERONA trial, anti-VEGF, ocular drug delivery